Please login to the form below
CNS
This page shows the latest CNS news and features for those working in and with pharma, biotech and healthcare.
Biogen pays InnoCare $125m upfront for potential multiple sclerosis treatment
system (CNS). ... Given the complex and chronic nature of MS, we believe the unique characteristics of orelabrutinib, combining high selectivity and CNS penetrance, may translate to potential clinical advantages relative to other BTKi
Latest news
-
Researchers publish promising results for ultra-rare disease gene therapy method
This work provides a framework for the treatment of other human CNS genetic diseases, and iterative refinement of the individual components of this approach will facilitate broader application,” they concluded. .
-
Anavex’s CNS drug slows progression of motor and non-motor symptoms in Parkinson’s disease
Independent research also strengthens the case that SIGMAR1 activation has a beneficial effect as a compensatory mechanism to chronic central nervous system (CNS) diseases. ... This data further strengthens the foundation of ANAVEX2-73 as a
-
AZ’s Tagrisso approved for EGFR-positive NSCLC in the EU
In addition, Tagrisso treatment also reduced the risk of central nervous system (CNS) recurrence or death by 82%, although median CNS DFS was not reached yet in either arm of the
-
Biogen and Envisagenics to advance RNA splicing research for CNS diseases
Biogen and Envisagenics are collaborating to advance ribonucleic acid (RNA) splicing research within the central nervous system (CNS) diseases area. ... Biogen will utilise Envisagenics’ artificial-intelligence (AI)-driven RNA splicing platform –
-
Biogen and Capsigen to collaborate on gene therapies
Biogen will gain exclusive right for undisclosed number of CNS and neuromuscular disease targets. ... Under the terms of the agreement, Biogen will gain an exclusive right under Capsigen’s proprietary technology for an undisclosed number of CNS and
Researchers publish promising results for ultra-rare disease gene therapy method
Anavex’s CNS drug slows progression of motor and non-motor symptoms in Parkinson’s disease
AZ’s Tagrisso approved for EGFR-positive NSCLC in the EU
Biogen and Envisagenics to advance RNA splicing research for CNS diseases
Biogen and Capsigen to collaborate on gene therapies
More from news
Approximately 6 fully matching, plus 188 partially matching documents found.
Latest Intelligence
-
Gut instincts lead Takeda to GI pipeline success
that focused the company’s R&D strategy on cutting-edge, innovative approaches in GI, oncology and the central nervous system (CNS).
-
The search for treatments for Parkinson’s disease
CNS disease drug development is traditionally viewed as higher risk and more expensive,” added Dr Roach.” I do not have privileged internal information about Pfizer’s neurological programmes, but many big ... Pfizer is probably in that category, so
-
Rethinking trials: the pros and cons of protocol amendments
We typically see more amendments in oncology and CNS. We also see a higher incidence and average number of amendments in later stage phase 2 and 3 studies.
-
China’s clinical trial shake-up
These reporting rules require sponsors to upload information such as endpoints and eligibility criteria to www.chinadrugtrials.org.cn.
-
Key considerations for disease- modifying Parkinson’s disease trials
By Dr Peter Schueler, Senior Vice President, Drug Development Services and Haichen Yang, Vice President, Global Therapeutic Lead, both at CNS, ICON plc.
Gut instincts lead Takeda to GI pipeline success
The search for treatments for Parkinson’s disease
Rethinking trials: the pros and cons of protocol amendments
China’s clinical trial shake-up
Key considerations for disease- modifying Parkinson’s disease trials
More from intelligence
Approximately 0 fully matching, plus 44 partially matching documents found.
Latest appointments
-
Ex-J&J exec Denice Torres joins bluebird bio’s board
During her time at J&J, Torres held several executive leadership roles including president of McNeil Consumer Healthcare and president of Janssen Pharmaceuticals, CNS.
-
New hires at FibroGen, Saniona and Turbine
He is a veteran biotech leader, with over 23 years of experience in rare diseases and CNS.
-
Axovant poaches Allergan’s and Teva’s chief medical and science officers
development. “We have a wonderful opportunity to develop life-changing medicines for patients with CNS diseases.
-
Damien McDevitt moves from GSK to Acadia Pharmaceuticals
At Acadia, which focuses on the development and commercialisation of medicines for central nervous system (CNS) disorders, McDevitt will report to the company’s president and chief executive officer Steve Davis. ... This expertise, combined with his
-
Ron Menezes joins Almirall’s Aqua Pharmaceuticals
Menezes joins the group from Depomed Pharmaceuticals, where he served as vice president of sales and sales operations, pain and CNS.
Ex-J&J exec Denice Torres joins bluebird bio’s board
New hires at FibroGen, Saniona and Turbine
Axovant poaches Allergan’s and Teva’s chief medical and science officers
Damien McDevitt moves from GSK to Acadia Pharmaceuticals
Ron Menezes joins Almirall’s Aqua Pharmaceuticals
More from appointments
Approximately 0 fully matching, plus 27 partially matching documents found.
Latest from PMHub
-
Are patient recruitment and retention rates rising or falling?
in central nervous system (CNS) and oncology trials. ... CNS trial dropout rates grew to 25.9% from 19.2. Oncology trial rates grew to 19.3% from 18.2%.
-
New recommendations to stimulate braver and bolder communications
Lilianna Husseini, Director Communications, Oncology, Pfizer Global. Heidi LaPensée, Brand Lead, CNS, Sanofi UK.
-
Diagnosing the lag in neuropsychiatric treatments
Unlike the other organs in our body, the central nervous system (CNS) is surrounded by the Blood Brain Barrier (BBB). ... To say the BBB presents a formidable challenge in CNS drug development is an understatement.
-
Innovative approaches in the treatment of multiple sclerosis
Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS), leading to progressive and permanent disability. ... In the central nervous system (CNS, which includes the brain, optic nerves and spinal cord),
-
Innovative approaches in the treatment of multiple sclerosis
Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS), leading to progressive and permanent disability. ... In the central nervous system (CNS, which includes the brain, optic nerves and spinal cord),
Are patient recruitment and retention rates rising or falling?
More from PMHub
Approximately 0 fully matching, plus 11 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Digital account director
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Understanding the ‘real world’ starts and ends with the patient
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- Sanofi raises profit forecast following positive Q2 results
- Biogen/Eisai push for second approval in Alzheimer’s disease
- Reducing primary care antibiotic use may not be enough to counter antimicrobial resistance
- SoftBank buys $5bn stake in Roche
- Live Webinar: Making Wearable Technology Scalable and Adoptable
- Live Webinar: Transforming the Future of Health & Aging from a Global Health & Social Impact Approach
- Investors respond positively to “strong” Eli Lilly results
- Amanda Pritchard becomes NHS England’s first female chief executive
- Biogen/Eisai push for second approval in Alzheimer’s disease
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Understanding the ‘real world’ starts and ends with the patient
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
PMHub
Origins Insights
Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...
Latest intelligence
- Ask the writers: Transitioning from academia to medical writing
- Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
- Strategic launch planning: familiar framework, new mindset
- By James Aird...
- Guide
- How to embrace behavioural science principles in healthcare MR...
